Quality of life among patients with multiple sclerosis and voiding dysfunction: a cross-sectional study.
Multiple sclerosis
Quality of life
Urinary symptoms
Journal
BMC urology
ISSN: 1471-2490
Titre abrégé: BMC Urol
Pays: England
ID NLM: 100968571
Informations de publication
Date de publication:
03 Jun 2020
03 Jun 2020
Historique:
received:
30
05
2019
accepted:
19
02
2020
entrez:
5
6
2020
pubmed:
5
6
2020
medline:
5
3
2021
Statut:
epublish
Résumé
Evaluating the usefulness of treatment requires a direct measurement of the health-related quality of life (QOL). Therefore, this study was carried out aiming to determine the QOL of patients with MS and voiding dysfunction. This cross-sectional study was carried out using multi-stage random cluster sampling method on 602 patients with MS in Isfahan, Iran. All data were collected through interviews using standard questionnaires including International Prostate Symptom Score (IPSS), and the Multiple Sclerosis Quality of Life-54 (MSQOL-54). Data were analyzed using descriptive and inferential statistical tests. The prevalence rate of mixed, irritative, and obstructive urinary symptoms was 52.2, 25.5, and 6.5%, respectively. The mixed symptom had the highest prevalence among men and women with rates of 56.5 and 51.1%, respectively. The prevalence of irritative and obstructive symptoms was, respectively, higher and statistically significant among women alone and men alone (P < 0.05). The prevalence of irritative symptoms was higher among patients with MS, EDSS score ≤ 3, disease duration of less than 5 years, and with clinically isolated syndrome. In addition, the prevalence of mixed symptoms was higher among patients with MS of over 30 years of age with a Pre-high school degree, severe disability, disease duration of over 10 years, and progressive MS; the difference was statistically significant (P < 0.05). There was a difference in the combined dimensions of physical and mental health of QOL between the two groups with and without urinary symptoms (P < 0.05). Logistic regression analysis revealed that there was a higher probability of a urinary problems among patients with MS and high age [3.273 (1.083-9.860); P = 0.035]. Mixed urinary symptoms are highly prevalent among MS patients and affect QOL dimensions. In order to improve QOL, more attention and focus should be paid to urinary problems in MS patients.
Sections du résumé
BACKGROUND
BACKGROUND
Evaluating the usefulness of treatment requires a direct measurement of the health-related quality of life (QOL). Therefore, this study was carried out aiming to determine the QOL of patients with MS and voiding dysfunction.
METHODS
METHODS
This cross-sectional study was carried out using multi-stage random cluster sampling method on 602 patients with MS in Isfahan, Iran. All data were collected through interviews using standard questionnaires including International Prostate Symptom Score (IPSS), and the Multiple Sclerosis Quality of Life-54 (MSQOL-54). Data were analyzed using descriptive and inferential statistical tests.
RESULTS
RESULTS
The prevalence rate of mixed, irritative, and obstructive urinary symptoms was 52.2, 25.5, and 6.5%, respectively. The mixed symptom had the highest prevalence among men and women with rates of 56.5 and 51.1%, respectively. The prevalence of irritative and obstructive symptoms was, respectively, higher and statistically significant among women alone and men alone (P < 0.05). The prevalence of irritative symptoms was higher among patients with MS, EDSS score ≤ 3, disease duration of less than 5 years, and with clinically isolated syndrome. In addition, the prevalence of mixed symptoms was higher among patients with MS of over 30 years of age with a Pre-high school degree, severe disability, disease duration of over 10 years, and progressive MS; the difference was statistically significant (P < 0.05). There was a difference in the combined dimensions of physical and mental health of QOL between the two groups with and without urinary symptoms (P < 0.05). Logistic regression analysis revealed that there was a higher probability of a urinary problems among patients with MS and high age [3.273 (1.083-9.860); P = 0.035].
CONCLUSIONS
CONCLUSIONS
Mixed urinary symptoms are highly prevalent among MS patients and affect QOL dimensions. In order to improve QOL, more attention and focus should be paid to urinary problems in MS patients.
Identifiants
pubmed: 32493262
doi: 10.1186/s12894-020-00590-w
pii: 10.1186/s12894-020-00590-w
pmc: PMC7268392
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
62Références
J Neurol Neurosurg Psychiatry. 2009 May;80(5):470-7
pubmed: 19372287
Epidemiol Health. 2017 Feb 19;39:e2017008
pubmed: 28231687
Neurourol Urodyn. 2016 Jan;35(1):48-54
pubmed: 25327401
Mult Scler. 2007 Jan;13(1):106-12
pubmed: 17294618
Eur J Neurol. 2014 Apr;21(4):648-53
pubmed: 24471827
J Neurol. 2002 Aug;249(8):1010-5
pubmed: 12195446
Int J Mol Sci. 2015 Jul 24;16(8):16920-52
pubmed: 26213927
Lancet Neurol. 2015 Jul;14(7):720-32
pubmed: 26067125
J Spinal Cord Med. 2013 Nov;36(6):632-7
pubmed: 24090205
Can Urol Assoc J. 2017 Mar-Apr;11(3-4):E110-E115
pubmed: 28360957
Compr Psychiatry. 2010 Mar-Apr;51(2):193-200
pubmed: 20152302
Eur J Epidemiol. 1999 Sep;15(8):717-22
pubmed: 10555615
Neurol Int. 2013 Nov 11;5(4):e23
pubmed: 24416487
Spinal Cord. 1997 Jan;35(1):33-6
pubmed: 9025217
Drugs. 2003;63(2):153-66
pubmed: 12515563
Eur Urol. 2008 Sep;54(3):543-62
pubmed: 18599186
BJU Int. 2003 Sep;92(4):409-14
pubmed: 12930430
Int Neurourol J. 2018 Mar;22(1):58-64
pubmed: 29609425
Int J MS Care. 2015 Jan-Feb;17(1):14-25
pubmed: 25741223
Dis Mon. 2013 Jul;59(7):261-8
pubmed: 23786660
Br Med J. 1965 May 15;1(5445):1265-9
pubmed: 14278814
Neurology. 2006 Jun 13;66(11):1696-702
pubmed: 16769943
Int J Urol. 1997 Jan;4(1):40-6
pubmed: 9179665
Semin Immunol. 2009 Dec;21(6):328-33
pubmed: 19775910
Int Braz J Urol. 2009 May-Jun;35(3):326-33
pubmed: 19538768
Ann Indian Acad Neurol. 2008 Oct;11(4):236-41
pubmed: 19893680
Age Ageing. 2006 Jan;35(1):16-24
pubmed: 16234314
eNeurologicalSci. 2017 May 13;7:37-43
pubmed: 29260023
J Neurol Sci. 2003 Nov 15;215(1-2):79-85
pubmed: 14568133
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
World J Mens Health. 2016 Dec;34(3):200-208
pubmed: 28053950
Neurourol Urodyn. 2016 Jan;35(1):39-43
pubmed: 25212666
J Urol. 1995 Jul;154(1):169-73
pubmed: 7539859
Neurourol Urodyn. 2017 Apr;36(4):1208-1213
pubmed: 27548624
Acta Neurol Belg. 2017 Mar;117(1):83-90
pubmed: 28092018
Neurology. 2007 Jun 5;68(23):1971-8
pubmed: 17548546
Chin Med J (Engl). 2016 Mar 20;129(6):645-50
pubmed: 26960366
Nat Clin Pract Urol. 2005 Oct;2(10):492-501
pubmed: 16474623
Korean J Urol. 2015 Apr;56(4):266-75
pubmed: 25874039
Adv Ther. 2017 Aug;34(8):1953-1965
pubmed: 28687936